Key Stats for Jazz Pharmaceuticals Stock
- 52-Week Range: $105 to $243
- Current Price: $237
- Street Mean Target: $249
- Street High Target: $307
- Analyst Consensus: 10 Buys / 7 Outperforms / 1 Hold / 1 Underperform
- TIKR Model Target (Dec. 2030): $250
Jazz Pharmaceuticals Posts Record Q1 Revenue as the August Ziihera Decision Approaches
Jazz Pharmaceuticals (JAZZ) posted its highest-ever first-quarter revenue of around $1.07 billion following Q1 2026 results on May 5, a 19% year-over-year gain fueled by double-digit growth across every promoted brand.
The company is a global biopharmaceutical firm built around three therapeutic pillars: sleep disorders (Xywav, Xyrem), epilepsy (Epidiolex), and oncology (Zepzelca, Ziihera, Modeyso, Rylaze).
Xywav, the low-sodium oxybate treatment that is the only FDA-approved therapy for idiopathic hypersomnia, grew net product sales 18% to $408.2 million, supported by around 425 net patient adds and approximately 16,600 active patients exiting the quarter.
Zepzelca delivered the most striking growth in the portfolio, with net product sales jumping 60% year-over-year to $101 million, driven by rapid uptake of the Zepzelca-plus-atezolizumab combination in the first-line maintenance setting for extensive-stage small cell lung cancer following its FDA approval in October 2025.
Epidiolex added 15% revenue growth to $249.8 million, with 16% volume growth in the quarter and ongoing investment in adult patients and long-term care facilities where penetration remains low.
The newest commercial product, Modeyso, generated $41 million in net product sales in its first full quarter following its August 2025 launch in H3 K27M-mutant diffuse midline glioma, with approximately 500 patients treated since launch.
CEO Renée Galá framed the quarter as a foundation for the year: “Building on our record year in 2025, we are pleased to share our results from an exceptionally strong first quarter, led by commercial execution across our highly differentiated products for sleep, epilepsies, and cancers.”
The company reaffirmed its 2026 full-year revenue guidance of $4.25 billion to $4.5 billion.
The most important number in the investment case is not in any of those results — it is a date: the FDA set a PDUFA target action date of August 25, 2026 for Ziihera (zanidatamab) in first-line HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA).
Ziihera’s HERIZON-GEA-01 trial showed median overall survival of more than 26 months in the triplet arm (zanidatamab plus tislelizumab plus chemotherapy), which management described as more than 6 months of additional median OS compared to prior studies in HER2-positive patients, and the therapy demonstrated activity regardless of PD-L1 status.
It has been more than 15 years since a new first-line HER2-targeted agent became available for metastatic gastric cancer, and Jazz’s commercial team estimates approximately 90% overlap between the biliary tract cancer accounts already treating patients with Ziihera and the GEA accounts that would need to adopt it after approval.
Wall Street Consensus on JAZZ: Strong Conviction, But the Bernstein Initiation Raises a Real Question
Jazz Pharmaceuticals stock carries a heavily bullish analyst distribution: 10 Buys, 7 Outperforms, 1 Hold, and 1 Underperform across 19 firms, with a Street mean target of around $249 and a high target of around $307.
The thesis Wall Street is underwriting is an EPS recovery story powered by an oncology ramp, with normalized EPS already printing at $6.34 in Q1 2026 and consensus expecting around $6.18 for Q2, around $6.36 for Q3, and around $6.34 for Q4.
Full-year 2026 EPS momentum is reinforced by what drove the Q1 beat: reported non-GAAP adjusted EPS of $6.34 against a consensus estimate of $4.57, a spread that reflects strong execution across the commercial portfolio before any meaningful Ziihera GEA contribution.
The Street mean target of around $249 implies roughly 5% upside from the current price of around $237, which is unusually thin conviction relative to the ratings distribution, and that compression tells the story of what has already moved.
Jazz Pharmaceuticals stock has run from around $106 to around $237 in the past year, a gain that has priced in the Ziihera priority review, the Q1 beat, and the Zepzelca first-line approval well ahead of August.
The outlier is the May 22 Piper Sandler upgrade to $301 from $232, justified by the analyst argument that JAZZ shares have not re-rated as much as they should given the breadth of the zanidatamab opportunity, including both the near-term GEA launch and the longer-term breast cancer and pan-tumor potential.
The counterpoint arrived the same week: Bernstein initiated with a Market Perform at $229, arguing the stock’s current price already reflects positive outcomes for both the Ziihera GEA launch and the high-risk EmpowHER breast cancer Phase 3 trial, leaving little margin for execution shortfalls.
The risk is specific and quantifiable: management guided to competitive pressure in the sleep business in the second half of 2026, including generic high-sodium oxybates building volume and potentially one or more wake-promoting agents entering the NT1 narcolepsy segment.
Is Jazz Pharmaceuticals Stock Fairly Valued Going Into the GEA Launch?
TIKR’s base case values Jazz Pharmaceuticals at approximately $250 by December 2030, implying around 5% total return from the current price of around $237, or roughly 1% annualized over 4.6 years.
At the low case, the TIKR model produces a stock price of around $225 by the end of the forecast period, a total return of approximately negative 5%, and an IRR of roughly negative 1%, the scenario where sleep franchise headwinds compound faster than oncology builds.
The mid case of approximately $281 (December 2034) implies around 18% total return from current levels, or roughly 2% annualized, anchored to around 6% revenue growth CAGR, around 40% net income margins, and around 17% EPS growth CAGR.
The high case lands at approximately $346, for around 46% total return and roughly 5% annualized IRR, driven by around 6% revenue growth CAGR and around 41% net income margins, with the key variable being the pace and breadth of zanidatamab adoption across GEA, metastatic breast cancer, and the pan-tumor basket.
JAZZ is fairly valued at current levels against the TIKR mid-case: the base scenario offers limited annualized return from here, and the stock needs the high-case oncology execution to generate returns that justify the current multiple versus alternatives.
The binary that resolves this before year-end is the August 25 PDUFA date, followed by the second interim overall survival analysis for the doublet arm of the HERIZON-GEA-01 trial expected midyear, and finally the ACTION trial readout for Modeyso in first-line use expected in late 2026 or early 2027.
Is Jazz Pharmaceuticals Stock a Good Investment Right Now?
Jazz Pharmaceuticals stock is fairly valued at current levels based on the TIKR model’s mid-case, which targets approximately $250 by December 2030 at roughly 1% annualized return from around $237.
Upside to the Street high target of around $307 requires successful zanidatamab launches in GEA and, eventually, breast cancer.
The August 25 PDUFA date is the near-term inflection point that determines whether the stock re-rates or consolidates.
What Is the Price Target for JAZZ Stock?
The Street mean target for Jazz Pharmaceuticals stock is approximately $249, with a high target of around $307 from 19 covering analysts, skewed toward 10 Buys and 7 Outperforms.
Piper Sandler holds the high target at around $301, citing incomplete re-rating for the zanidatamab opportunity.
Meanwhile, the TIKR model’s mid-case target is approximately $250 by December 2030, consistent with the Street mean but implying only modest near-term upside from current levels.
Should You Invest in Jazz Pharmaceuticals plc?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Jazz Pharmaceuticals plc stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Jazz Pharmaceuticals plc alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze JAZZ stock on TIKR for Free →
